Search research articles
Contact Us
Filters
Showing results (71-80 of 93) with videos related to
Page
of 10
Sort By:
Cancers
|
October 16, 2025
Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab
Tai-Chi Wu, Po-Ting Lin, Wei Teng, et al.
Clinical Lung Cancer
|
July 6, 2016
Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery
Kai-Lin Yang, Yih-Chen Chang, Hui-Ling Ko, et al.
European Journal of Gastroenterology & Hepatology
|
December 19, 2019
Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 10, 2019
The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, et al.
American Journal of Cancer Research
|
April 9, 2024
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor
Po-Ting Lin, Yu-Chun Hsu, Yu-Ting Kao, et al.
American Journal of Cancer Research
|
August 6, 2021
MELD score is the better predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by trans-arterial embolization
Ya-Ting Cheng, Wei Teng, Kar-Wai Lui, et al.
Pharmacogenomics
|
February 13, 2016
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization
Kung-Hao Liang, Chih-Lang Lin, Sung-Fang Chen, et al.
American Journal of Cancer Research
|
May 9, 2022
Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Wei Teng, Chen-Chun Lin, Chung-Wei Su, et al.
Journal of Clinical and Translational Hepatology
|
March 11, 2026
Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis
Yuan-Hung Kuo, Wei Teng, Yen-Hao Chen, et al.
Cancer Medicine
|
December 5, 2022
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma
Chung-Wei Su, Wei Teng, Po-Ting Lin, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 93) with videos related to
Sort By:
Page
of 10
Cancers
|
October 16, 2025
Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab
Tai-Chi Wu, Po-Ting Lin, Wei Teng, et al.
Clinical Lung Cancer
|
July 6, 2016
Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery
Kai-Lin Yang, Yih-Chen Chang, Hui-Ling Ko, et al.
European Journal of Gastroenterology & Hepatology
|
December 19, 2019
Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 10, 2019
The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, et al.
American Journal of Cancer Research
|
April 9, 2024
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor
Po-Ting Lin, Yu-Chun Hsu, Yu-Ting Kao, et al.
American Journal of Cancer Research
|
August 6, 2021
MELD score is the better predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by trans-arterial embolization
Ya-Ting Cheng, Wei Teng, Kar-Wai Lui, et al.
Pharmacogenomics
|
February 13, 2016
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization
Kung-Hao Liang, Chih-Lang Lin, Sung-Fang Chen, et al.
American Journal of Cancer Research
|
May 9, 2022
Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Wei Teng, Chen-Chun Lin, Chung-Wei Su, et al.
Journal of Clinical and Translational Hepatology
|
March 11, 2026
Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis
Yuan-Hung Kuo, Wei Teng, Yen-Hao Chen, et al.
Cancer Medicine
|
December 5, 2022
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma
Chung-Wei Su, Wei Teng, Po-Ting Lin, et al.
Page
of 10